RAC - Charts & Price Action, page-40

I just think it’s important to separate the patents from agreements to use/exchange/share IP. It can easily create confusion if you don’t use the right terms.

RACE’s own patents for Bisantrene are distinct from any agreements to combine it with specific drugs. The combination patent generically covers the use of Bisantrene with other agents. RACE have this combination patent.

Then separately you have agreements between organisations to mutually share / exchange IP for a common goal but with a certain constrained scope and with certain terms and conditions. That’s an IP licensing issue, not a patent issue. I’ve seen this sort of thing for my work ( background is software, so understand the principles ).

“Squabbling” - I think DrT was really just bemused by the quite normal back and forth for nailing down the nitty gritty of commercial agreements for use of IP. I’ve also seen this sort of squabbling in my own work (and it was also to my bemusement).